The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | H | Systemic hormonal preparations, excl. Sex hormones and insulins | |
| 2 | H01 | Pituitary and hypothalamic hormones and analogues | |
| 3 | H01C | Hypothalamic hormones | |
| 4 | H01CB | Somatostatin and analogues | |
| 5 | H01CB05 | Pasireotide |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Route | Amount |
|---|---|
| PAREN - Parenteral | 1.2 mg |
| Active Ingredient | Description | |
|---|---|---|
| Pasireotide |
Pasireotide is a novel cyclohexapeptide, injectable somatostatin analogue. Pasireotide exerts its pharmacological activity via binding to somatostatin receptors. Somatostatin receptors are expressed in many tissues, especially in neuroendocrine tumours in which hormones are excessively secreted, including ACTH in Cushing’s disease. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| SIGNIFOR LAR Suspension for injection | Health Products and Food Branch (CA) | MPI, CA: SPM | |
| SIGNIFOR Powder and solvent for suspension for injection | European Medicines Agency (EU) | MPI, EU: SmPC | |
| SIGNIFOR Solution for injection | European Medicines Agency (EU) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
